Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (129)	7/27/1997 8:52:00 PM
From: scaram(o)uche	Respond to of 3557

Miljenko: The data presented has been largely published. The major points (all very early stuff)....... Ang-2 also binds TIE-2, but does not activate. It blocks the activator, ang-1. VEGF and Ang-1 act in concert for normal vessel formation in the embryo, and VEGF perhaps sensitizes for ang-2. In the adult, ang-2 is only expressed in the ovary, uterus and placenta, and may destabilize the vasculature or actually sensitize for VEGF. Ovarian follicles will tell an interesting story. Because of the tissue distribution (or lack thereof) of ang-2 in the adult, they are rapidly moving to studies of tumor vascular formation. Ang-2 may be the earliest tumor marker, even preceeding VEGF. There was a lot of speculation. This made for an interesting presentation, but I had trouble determining where they were headed. I presume that the emphasis is on ang-2. On one handout, Dr. Y. showed ang-2 inhibiting the effects of ang-1 on endothelial-mesenchymal interactions, vascular stabilization and branch formation. Note: this presentation would have been way over my head, even if I hadn't been nursing the headache from hell. I stuck around to see this presentation and then wandered off to be [very] sick. :-( If your primary interest is in positive regulation, then ang-1 is your baby. No, there was no preclinical data shown for disease models. And, no, I didn't attend the Suppressors/Oncogene conference. Cheers! Rick